Q2 2025 Earnings Call Transcript July 22, 2025 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $5.3, expectations were $2.57. Operator: Welcome to the Quest Diagnostics ...

Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J ...

Quest will base the test on a developmental license to technology and intellectual property associated with the Multi-Cancer Stratification Test (MCaST), a cohesive risk model developed by the ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

See details about Quest Diagnostics's self-order lab testing, at-home diagnostic tests, and its app.

Quest Diagnostics teamed up with Google Cloud. The collaboration seeks to deliver new AI capabilities — including predictive population health analytics, customized physician results reporting ...

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical Care—including services that Quest will then provide back to Fresenius as | The ...

Quest Diagnostics DGX is gaining from advanced diagnostics offerings and strategic acquisitions. Rising debts and industry challenges continue to dent growth. The stock carries a Zacks Rank #3 (Hold).

Quest Diagnostics (DGX -0.81%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades.

University Hospitals completes sale of about 50 outpatient lab services locations in Ohio to New Jersey-based Quest.